1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Gamunex-C: new trials by email Literature Review of Gamunex-C trials Research Report on Gamunex-C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Gamunex-C, Albumin - Immune-Mediated Necrotizing Myopathy | Phase 2 | Withdrawn | University of Washington | 2022-05-01 | 2022-10-24 | |
| Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) GAMUNEX-C, Standard Medical Treatment - COVID-19 | Phase 2 | Completed | Grifols Therapeutics LLC | 100 | 2020-09-17 | 2022-10-07 |
COVID-19 (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Virus Diseases (1)
Grifols Therapeutics LLC (1) · University of Washington (1)
United States (2)
James S Andrews, MD (1) · Simon Mahler, MD (1)